The US Food and Drug Administration has proposed a new rule that would allow drug manufacturers using a hub-and-spoke model to register multiple facilities as a single establishment, reducing administrative burdens. Under the current framework, each manufacturing unit must register separately, but the proposed change would streamline the process and permit companies to add, relocate, or remove units after notifying the FDA. The rule would also require foreign establishments that produce drugs or components solely for overseas use to register with the FDA and report their products, closing a gap that limits visibility into upstream supply chains. Michael Davis, acting director of the FDA's Center for Drug Evaluation and Research, said the changes would make it easier for innovative manufacturers to operate efficiently and give the agency a clearer picture of where drugs are made. The proposal aligns with broader US efforts to bolster domestic pharmaceutical manufacturing and supply chain transparency.